|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/4433 | (2006.01) |
| A61K 31/4166 | (2006.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/04 | (2006.01) |
| (11) | Number of the document | 4247371 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21827282.1 |
| Date of filing the European patent application | 2021-11-18 | |
| (97) | Date of publication of the European application | 2023-09-27 |
| (45) | Date of publication and mention of the grant of the patent | 2025-01-01 |
| (46) | Date of publication of the claims translation | 2025-04-10 |
| (86) | Number | PCT/US2021/059847 |
| Date | 2021-11-18 |
| (87) | Number | WO 2022/109106 |
| Date | 2022-05-27 |
| (30) | Number | Date | Country code |
| 202063115165 P | 2020-11-18 | US |
| (72) |
BRADLEY, William, D. , US
CUI, Jike , US
SUN, Kaiming , US
TROJER, Patrick , US
WANG, Jing , US
WU, Rentian , US
|
| (73) |
Constellation Pharmaceuticals, Inc. ,
470 Atlantic Avenue, Suite 1401, Boston, MA 02210,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | EZH2 slopinimo terapija, skirta prostatos vėžio formoms su mutavusiu androgenų receptoriumi gydyti |
| EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF ANDROGEN RECEPTOR MUTATED PROSTATE CANCERS |